References
- Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11–25.
- Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981–9.
- Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci 2006;97:243–7.
- Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators. Androgen deprivation therapy as primary treatment for localized prostate cancer: data from cancer of the prostate strategic urologic research endeavor (CaPSURE). Cancer 2006;106:1708–14.
- Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724–31.
- Daehlin L, Tomic R, Damber JE. Depressed testosterone release from testicular tissue in vitro after withdrawal of estrogen treatment in patients with prostate carcinoma. Scand J Urol Nephrol 1988;22:11–13.
- Johansen TE, Ogreid P, Kjellevold K, Blom P. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate. Br J Urol 1990;65:376–8.
- Bong GW, Clarke HS, Hancock WC, Keane TE. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology 2008;71:1177–80.
- Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwtiz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895–903.
- Fujimoto N, Kubo T, Tomisaki I. Cessation of primary androgen deprivation therapy for men with localized prostate cancer. Clin Genitourin Cancer 2015;13:359–63.
- Pedraza R, Kwart AM. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression? Urology 2003;61:770–3.
- Kobayashi T, Nishizawa K, Mitsumori K. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer. Scand J Urol Nephrol 2006;40:198–203.
- Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999;53:898–903.
- Kaku H, Tsushima T, Nasu Y, Kumon H. Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer. Nippon Rinsho 2002;11:182–7.
- Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000;164:1891–4.
- Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998;160:1685–8.